Searched for
LUPIN GROWTH
Biosimilars and innovation will drive Indian pharma's next growth phase: Vishal ManchandaIndia's pharmaceutical sector is pivoting beyond generics, with companies aggressively pursuing growth in biosimilars, nutraceuticals, and ...- Sunil Singhania-backed Abakkus Flexi Cap Fund increases stake in HDFC Bank, RIL and 29 others in MaySunil Singhania-backed Abakkus Flexi Cap Fund significantly increased its holdings in HDFC Bank and Reliance Industries during May. The fun...
- These large- and mid-cap stocks can give more than 25% return in 1 year, according to analystsThere are market phases when one risk dominates. Then there are phases like this, when risks arrive from every direction and refuse to stan...
- Sweet pills: How pharma stocks delivered bumper returns to Indian investors, defying 2026 whiplashIndian pharma stocks are outperforming the market, offering strong returns to investors. This resilience is driven by robust domestic deman...
- Bernstein initiates coverage on 6 pharma stocks, cites 3 major tailwinds for healthcare sectorBernstein has initiated coverage on six Indian pharma stocks, with Zydus Lifesciences as its top choice. The brokerage sees strong future g...
- Laurus Labs adds Rs 40,150 crore to investors' wealth in a year with 120% rally. Buy, hold or book profits?Laurus Labs has significantly boosted investor wealth, adding over Rs 40,000 crore in a year with a 120% stock rally. Driven by business im...
- Mutual funds cut technology sector exposure to 8-year low in April. Is AI disruption reshaping sentiment?Mutual funds have significantly reduced their technology sector exposure to an eight-year low, driven by concerns over AI disruption, slowi...
- Doing more with less is India Inc's new mantra to beat tough timesPrioritising efficiency, Indian enterprises are reshaping their spending habits. Non-essential travel and expenses are being minimized, whi...
- Suryoday Small Finance Bank reports Q4 profit at Rs 49 croreSuryoday Small Finance Bank reported a strong turnaround in fourth-quarter earnings with improved profitability and higher operating profit...
- Small & midcaps rally! Wockhardt, Coforge, other stocks surge up to 14%. Do you own any?Smallcap and midcap stocks surged on Wednesday, outperforming broader market indices with gains of around 1% each. This rally was fueled by...
- Pharma Q4 outlook mixed: Hospitals steady, generics face revlimid dragIndian pharma and healthcare firms face a mixed March quarter. While hospitals anticipate steady growth, generic drugmakers grapple with lo...
- El Nino impact: Which stocks will burn & which will fire up as market braces for heat waveIndia faces a strong El Niño, threatening below-normal rainfall and impacting agriculture. While rural-linked sectors like two-wheelers and...
- Bain Capital sole contender for Vitabiotics buyBain Capital has emerged as the frontrunner to acquire Vitabiotics, as rival bidders TPG Capital and EQT exit the process, potentially lowe...
- Stocks in news: HDFC Bank, ICICI Bank, RIL, Trent, Jio FinancialIndian markets are set for a dynamic start today. Investors will closely watch the Q4 results from banking giants HDFC Bank and ICICI Bank....
- Time to buy? Sunny Agrawal finds best picks across banking, pharma, capital markets & infrastructureIndian stock markets present attractive opportunities now. Investors with an 18-month outlook should consider deploying funds, especially i...
- Lupin shares jump 2% as Q2 PAT soars 73% YoY to Rs 1,485 croreLupin shares rose on Friday after the pharma major reported a robust 73% YoY surge in Q2 FY26 PAT to Rs 1,485 crore, driven by strong sales...
- Lupin subsidiary inks pact to acquire Netherlands-based VISUfarmaLupin's subsidiary will acquire VISUfarma BV for 190 million euros. This expands Lupin's European business and eye health product range. Th...
- Lupin completes acquisition of portfolio of brands from Anglo-French Drugs & Industries"India is critical in shaping Lupin's growth story going forward. This acquisition strengthens our position in the Indian market, where we ...
- Lupin expects single digit sales growth this fiscalThe drug maker reported negative growth in 2017-18 for the first time in a decade, with net sales dropping to Rs 15,560 crore, a decline of...
- US Generic launches are key to Lupin growthLupin's revenue grew 5% yearon-year to Rs 3,144.9 crore during the December 2014 quarter, much lower than the analysts' expectation of 12-1...
Load More
